Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance
Novartis has packaged and priced Kisqali – the second CDK4/6 inhibitor approved in the US – to compete with Pfizer's Ibrance, which made the mechanism of action the standard of care in untreated metastatic HR+/HER2- breast cancer.
You may also be interested in...
Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space
Data at ASCO showed a statistically significant overall survival advantage in pre- and perimenopausal women with advanced HR+, HER2- breast cancer, a first for the CDK4/6 class.
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
The latest drug development news and highlights from our US FDA Performance Tracker.
CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie
Pfizer's Ibrance has a strong lead in the CDK4/6 space, but Novartis' Kisqali and Lilly's Verzenio are looking to carve out their own niches, expand the category and move into earlier treatment settings. Another scramble is on as well, to answer the question: what comes next?